Page last updated: 2024-08-26

selenazofurin and 3-(1-deoxyribofuranosyl)benzamide

selenazofurin has been researched along with 3-(1-deoxyribofuranosyl)benzamide in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (66.67)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cooney, DA; Gharehbaghi, K; Hao, Z; Jayaram, HN; Krohn, K; Paull, KD; Sreenath, A; Szekeres, T	1
Cooney, DA; Grusch, M; Jayaram, HN; Krupitza, G	1
Gharehbaghi, K; Grünberger, W; Jayaram, HN	1

Reviews

1 review(s) available for selenazofurin and 3-(1-deoxyribofuranosyl)benzamide

Article	Year
Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis. Current medicinal chemistry, 1999, Volume: 6, Issue:7 Topics: Antineoplastic Agents; Apoptosis; cdc25 Phosphatases; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Guanosine Triphosphate; HL-60 Cells; Humans; IMP Dehydrogenase; Leukemia, Myeloid; Neoplasms; Nucleosides; Organoselenium Compounds; Ovarian Neoplasms; Protein Tyrosine Phosphatases; Ribavirin; Ribonucleosides; RNA, Messenger; Time Factors; Tumor Cells, Cultured	1999

Article

Year

Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis.

Current medicinal chemistry, 1999, Volume: 6, Issue:7

Topics: Antineoplastic Agents; Apoptosis; cdc25 Phosphatases; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Guanosine Triphosphate; HL-60 Cells; Humans; IMP Dehydrogenase; Leukemia, Myeloid; Neoplasms; Nucleosides; Organoselenium Compounds; Ovarian Neoplasms; Protein Tyrosine Phosphatases; Ribavirin; Ribonucleosides; RNA, Messenger; Time Factors; Tumor Cells, Cultured

1999

Other Studies

2 other study(ies) available for selenazofurin and 3-(1-deoxyribofuranosyl)benzamide

Article	Year
Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin. Biochemical pharmacology, 1994, Oct-07, Volume: 48, Issue:7 Topics: Antineoplastic Agents; Cell Survival; Glutamate Dehydrogenase; Humans; IMP Dehydrogenase; L-Lactate Dehydrogenase; Malate Dehydrogenase; Nucleosides; Organoselenium Compounds; Ribavirin; Ribonucleosides; Ribonucleotides; Tumor Cells, Cultured	1994
Studies on the mechanism of action of benzamide riboside: a novel inhibitor of IMP dehydrogenase. Current medicinal chemistry, 2002, Volume: 9, Issue:7 Topics: Antineoplastic Agents; Cell Survival; Central Nervous System Neoplasms; Humans; IMP Dehydrogenase; Isoenzymes; Nucleosides; Organoselenium Compounds; Ribavirin; Ribonucleosides; Sarcoma; Tumor Cells, Cultured	2002

Article

Year

Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin.

Biochemical pharmacology, 1994, Oct-07, Volume: 48, Issue:7

Topics: Antineoplastic Agents; Cell Survival; Glutamate Dehydrogenase; Humans; IMP Dehydrogenase; L-Lactate Dehydrogenase; Malate Dehydrogenase; Nucleosides; Organoselenium Compounds; Ribavirin; Ribonucleosides; Ribonucleotides; Tumor Cells, Cultured

1994

Studies on the mechanism of action of benzamide riboside: a novel inhibitor of IMP dehydrogenase.

Current medicinal chemistry, 2002, Volume: 9, Issue:7

Topics: Antineoplastic Agents; Cell Survival; Central Nervous System Neoplasms; Humans; IMP Dehydrogenase; Isoenzymes; Nucleosides; Organoselenium Compounds; Ribavirin; Ribonucleosides; Sarcoma; Tumor Cells, Cultured

2002